In this article
View / Download pdf version
of this article
Improving the care of children with asthma
Studies suggest that the majority of children with asthma do not have good control. This appears to be associated
with low asthma pharmaceutical use compared to the recommendations of asthma management guidelines.
Asthma has been identified as one of the most heavily under treated diseases. In children there is low usage of long
acting beta agonists (LABAs) despite high average daily doses of inhaled corticosteroids.
The majority of children with asthma, especially Māori children, do
not have good control of their asthma
New Zealand has one of the highest asthma prevalence rates in the world. It affects over 200,000 children, which is
approximately one in four. Rates of hospital admissions due to asthma are highest in children, being about double that
of adults, with the majority occurring in children under five years.
Although the prevalence of childhood asthma in New Zealand is similar for Māori and non-Māori, Māori children with asthma
have more severe symptoms when presenting for routine or acute asthma care, require more time off school because of asthma
and require hospitalisation for asthma almost twice as often as non-Māori children. While admission rates for childhood
asthma have gradually decreased in New Zealand Europeans, rates for Māori and Pacific children have risen.
Despite increased need for good asthma management Māori children are less likely to receive adequate education, have
an asthma action plan or be prescribed preventive medication. Other commonly cited barriers for Māori with asthma include
cost for consultation, access to transport and telephone and the attitude of the doctor/provider including bias and discrimination.
Implementation of The Paediatric Society of New Zealand evidence based guideline ‘Management of Asthma in Children Aged
1-15 Years’ should lead to improved asthma outcomes for all children. LABAs do not feature in the management of asthma
in children under the age of four years for primary care but its use in children aged 5-15 years is well represented in
the following algorithm from the guideline.
The text for this article is adapted from: Asher I, Byrnes C, Editors ‘Trying to Catch Our Breath - The Burden of Preventable
Breathing Diseases in Children and Young People.’ The Asthma and Respiratory Foundation, 2006.
Summary of Stepwise Pharmacological Management in Children Aged 5-15 Years
Get a PDF of this summary here
||Mild Intermittent Asthma
Inhaled shortacting ß2 agonist as required
||Regular Preventer Therapy
Add inhaled steroid 200-400 microgram/day beclomethasone dipropionate (BDP) or budesonide (BUD) , or
100-200 microgram/day fluticasone
- use the higher dose for greater severity, (cromoglycate, nedocromil or montelukast1 if inhaled steroid
cannot be used)
||Add on Therapy
1. Add inhaled long acting ß2 agonist (LABA)2 2. Assess response to LABA:
- good response to LABA - continue LABA
some benefit from LABA in maximum dose but control still inadequate,
increase inhaled steroid to 400 microgram/day BDP or BUD, or 200 microgram/day FP (if not already
on this dose)
- no response to LABA - Stop LABA consider trial of montelukast or SR theophylline
||Persistent Poor Control
Increase inhaled steroid to 600-800 microgram/day BDP or BUD, or 300-400 microgram/day fluticasone3
Continue to review add on therapy
Refer to paediatrician if not improving
||Continued Poor Control
Refer to paediatrician
Maintain high dose inhaled steroid
Consider steroid tablet in lowest dose providing adequate control
- The only NZ Registered Leukotriene Receptor Antagonist , montelukast , is not currently on the Pharmaceutical Schedule.
- Maximum recommended dose of eformoterol is 12 microgram/bd, and salmeterol 50 microgram/bd.
- These levels of ICS are greater than usually required to achieve optimal control, do not hesitate to seek advice from
Montelukast is now funded in New Zealand under Special Authority. For more information, see
"Assessing wheeze in pre-school children", BPJ 56 (November, 2013).
The algorithm is taken from: ‘Management of Asthma in Children Aged 1-15 Years’ Paediatric Society of New Zealand